Christopher Ritchlin

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Altered bone biology in psoriatic arthritis
    Homaira Rahimi
    Department of Pediatrics, Division of Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 777, Rochester, NY 14642, USA
    Curr Rheumatol Rep 14:349-57. 2012
  2. ncbi Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
    James J Kobie
    Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R209. 2011
  3. ncbi Biomarker development in psoriatic arthritis
    Christopher Ritchlin
    Allergy, Immunology and Rheumatology Division, the Center for Musculoskeletal Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Rheumatol Suppl 89:57-60. 2012
  4. ncbi GRAPPA Trainees Symposium 2010: a report from the GRAPPA 2010 annual meeting
    Christopher T Ritchlin
    Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Rheumatol 39:394-7. 2012
  5. ncbi Strategies for biomarker development in psoriatic disease: a report from the GRAPPA 2010 annual meeting
    Christopher T Ritchlin
    Allergy, Immunology, and Rheumatology Division, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Rheumatol 39:423-6. 2012
  6. ncbi CD23(+)/CD21(hi) B-cell translocation and ipsilateral lymph node collapse is associated with asymmetric arthritic flare in TNF-Tg mice
    Jie Li
    Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R138. 2011
  7. ncbi Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
    Dafna D Gladman
    University of Toronto, 399 Bathurst Street, Room 1E 410B, Toronto, Ontario M5T 2S8, Canada
    Arthritis Res Ther 12:R113. 2010
  8. ncbi CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis
    Yahui Grace Chiu
    Allergy Immunology and Rheumatology Unit, University of Rochester Medical School, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arthritis Res Ther 12:R14. 2010
  9. ncbi Treatment recommendations for psoriatic arthritis
    C T Ritchlin
    Clinical Immunology Research Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, New York 14642, USA
    Ann Rheum Dis 68:1387-94. 2009
  10. ncbi Translational perspectives on psoriatic arthritis
    Christopher T Ritchlin
    University of Rochester Medical Center, Rochester, New York, USA
    J Rheumatol Suppl 83:30-4. 2009

Collaborators

Detail Information

Publications47

  1. ncbi Altered bone biology in psoriatic arthritis
    Homaira Rahimi
    Department of Pediatrics, Division of Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 777, Rochester, NY 14642, USA
    Curr Rheumatol Rep 14:349-57. 2012
    ..Lastly, we discuss promising therapies that target joint inflammation and osteitis with the potential to mediate pathologic bone formation...
  2. ncbi Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
    James J Kobie
    Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R209. 2011
    ..Therefore, we asked if short-term effector (d5-d10) and memory (1 month or later) B cell responses to antigen were compromised in RA patients treated with anti-TNF therapy...
  3. ncbi Biomarker development in psoriatic arthritis
    Christopher Ritchlin
    Allergy, Immunology and Rheumatology Division, the Center for Musculoskeletal Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Rheumatol Suppl 89:57-60. 2012
    ....
  4. ncbi GRAPPA Trainees Symposium 2010: a report from the GRAPPA 2010 annual meeting
    Christopher T Ritchlin
    Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Rheumatol 39:394-7. 2012
    ..Nineteen posters and 6 oral presentations were presented by the trainees, all of which are summarized here...
  5. ncbi Strategies for biomarker development in psoriatic disease: a report from the GRAPPA 2010 annual meeting
    Christopher T Ritchlin
    Allergy, Immunology, and Rheumatology Division, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Rheumatol 39:423-6. 2012
    ....
  6. ncbi CD23(+)/CD21(hi) B-cell translocation and ipsilateral lymph node collapse is associated with asymmetric arthritic flare in TNF-Tg mice
    Jie Li
    Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R138. 2011
    ....
  7. ncbi Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
    Dafna D Gladman
    University of Toronto, 399 Bathurst Street, Room 1E 410B, Toronto, Ontario M5T 2S8, Canada
    Arthritis Res Ther 12:R113. 2010
    ..To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT)...
  8. ncbi CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis
    Yahui Grace Chiu
    Allergy Immunology and Rheumatology Unit, University of Rochester Medical School, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arthritis Res Ther 12:R14. 2010
    ..Our previous studies showed an elevated frequency of OC precursors (OCP) in PsA patients. Here, we examined if OC arise from CD16-positive monocytes in PsA...
  9. ncbi Treatment recommendations for psoriatic arthritis
    C T Ritchlin
    Clinical Immunology Research Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, New York 14642, USA
    Ann Rheum Dis 68:1387-94. 2009
    ..To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion...
  10. ncbi Translational perspectives on psoriatic arthritis
    Christopher T Ritchlin
    University of Rochester Medical Center, Rochester, New York, USA
    J Rheumatol Suppl 83:30-4. 2009
    ..These translational studies point to potential biomarkers of arthritis in psoriasis patients and generate alternative hypotheses to explain the events that lead to arthritic flare...
  11. ncbi Therapies for psoriatic enthesopathy. A systematic review
    Christopher T Ritchlin
    Clinical Immunology Research Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Rheumatol 33:1435-8. 2006
    ..In this evidence-based review, we assess the limited data on treatments for enthesitis and make recommendations for further studies in psoriatic enthesitis...
  12. ncbi Efficacy and safety of infliximab for the treatment of psoriatic arthritis
    Christopher Ritchlin
    University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Nat Clin Pract Rheumatol 2:300-1. 2006
  13. ncbi Newer therapeutic approaches: spondyloarthritis and uveitis
    Christopher Ritchlin
    Clinical Immunology Research Unit, Allergy Immunology and Rheumatology Division, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Rheum Dis Clin North Am 32:75-90, viii. 2006
    ..This article summarizes treatment advances in SpA with emphasis on the efficacy and safety of biologic agents in the treatment of psoriatic arthritis, ankylosing spondylitis, undifferentiated spondyloarthropathy, and uveitis...
  14. ncbi From skin to bone: translational perspectives on psoriatic disease
    Christopher T Ritchlin
    Clinical Immunology Research Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Rheumatol 35:1434-7. 2008
    ....
  15. ncbi Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis
    C Ritchlin
    Clinical Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    Arthritis Res 2:356-60. 2000
    ....
  16. ncbi Pathogenesis of psoriatic arthritis
    Christopher T Ritchlin
    University of Rochester Medical Center, Rochester, New York 14642, USA
    Curr Opin Rheumatol 17:406-12. 2005
    ..This review examines relevant animal models and genetic factors implicated in disease susceptibility. Also, recent reports on mechanisms related to synovial and entheseal inflammation are discussed...
  17. ncbi Treatment of reactive arthritis with azithromycin
    Christopher T Ritchlin
    Curr Rheumatol Rep 7:171. 2005
  18. ncbi Doxycycline in undifferentiated spondyloarthropathy
    Christopher T Ritchlin
    Curr Rheumatol Rep 7:171-2; discussion 172. 2005
  19. ncbi Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists
    C T Ritchlin
    Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Best Pract Res Clin Rheumatol 24:683-92. 2010
    ....
  20. ncbi Recent advances in the treatment of the seronegative spondyloarthropathies
    C T Ritchlin
    Allergy Immunology and Rheumatology Unit, Strong Memorial Hospital University of Rochester Medical Center, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Curr Rheumatol Rep 3:399-403. 2001
    ....
  21. ncbi Expression of interleukin 10 mRNA and protein by synovial fibroblastoid cells
    C Ritchlin
    Clinical Immunology Rheumatology Unit, University of Rochester School of Medicine and Dentistry, New York 14642, USA
    J Rheumatol 28:698-705. 2001
    ..To determine if fibroblast-like synoviocytes (FLS) express interleukin 10 (IL-10) mRNA and protein and functional IL-10 receptors...
  22. ncbi Psoriatic disease--from skin to bone
    Christopher Ritchlin
    University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Nat Clin Pract Rheumatol 3:698-706. 2007
    ....
  23. ncbi High-resolution interleaved water-fat MR imaging of finger joints with chemical-shift elimination
    Wingchi E Kwok
    Department of Imaging Sciences, University of Rochester, Rochester, New York, USA
    J Magn Reson Imaging 33:245-51. 2011
    ..To study the use of an interleaved water-fat (IWF) sequence with a custom-made radiofrequency (RF) coil for high-resolution imaging of arthritic finger joints...
  24. ncbi High-resolution uniform MR imaging of finger joints using a dedicated RF coil at 3T
    Wingchi E Kwok
    Department of Imaging Sciences, University of Rochester, Rochester, New York, USA
    J Magn Reson Imaging 31:240-7. 2010
    ..To develop a dedicated radiofrequency (RF) coil for high-resolution magnetic resonance imaging (MRI) of finger joints at 3T to improve diagnostic evaluation of arthritic diseases...
  25. ncbi From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    J Am Acad Dermatol 58:94-105. 2008
    ..Biologics are widely used in the treatment of psoriasis and psoriatic arthritis...
  26. ncbi Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein
    R Zeltser
    University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Arch Dermatol 137:893-9. 2001
    ..CONCLUSIONS: Injection site reactions associated with etanercept therapy are common, and may be an example of a T-lymphocyte-mediated delayed-type hypersensitivity reaction, with waning over time due to eventual induction of tolerance...
  27. ncbi Treatment update on spondyloarthropathy. From NSAIDs and DMARDs to anti-TNF-alpha agents
    Allen P Anandarajah
    Department of Allergy, Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, New York 14642, USA
    Postgrad Med 116:31-6, 39-40. 2004
    ..Here, Drs Anandarajah and Ritchlin explore the effectiveness of conventional therapies as well as biologic agents that are currently available or under development...
  28. ncbi Treatment update on spondyloarthropathy
    Allen Anandarajah
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York, USA
    Curr Opin Rheumatol 17:247-56. 2005
    ..Information from these trials will more clearly define the role of disease-modifying antirheumatic drugs, novel therapeutic agents, and antibiotics in the treatment of spondylarthropathy...
  29. ncbi Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Washington 98104, USA
    Arthritis Rheum 52:3279-89. 2005
    ..Adalimumab, a fully human, anti-tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA)...
  30. ncbi Etanercept in psoriatic arthritis
    Allen P Anandarajah
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    Expert Opin Biol Ther 3:169-77. 2003
    ..In summary, etanercept is a safe and effective agent for the treatment of PsA and represents a major advance in the therapy of this potentially crippling disease...
  31. ncbi Autoimmunity and bone
    Edward M Schwarz
    Department of Orthopaedics, University of Rochester Medical Center, 601 Elmwood Avenue, Box 665, Rochester, NY 14642, USA
    Ann N Y Acad Sci 1068:275-83. 2006
    ..Thus, systemic factors produced by autoimmunity have a dramatic impact on active myelopoiesis and bone homeostasis...
  32. ncbi Altered bone remodeling in psoriatic arthritis
    Kofi A Mensah
    Department of Orthopaedics, University of Rochester Medical Center, 601 Elmwood Avenue, Box 665, Rochester, NY 14642, USA
    Curr Rheumatol Rep 10:311-7. 2008
    ..It also discusses the effects of tumor necrosis factor inhibition on bone resorption and new bone formation in PsA...
  33. ncbi Pathogenesis of psoriatic arthritis
    Allen P Anandarajah
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    Curr Opin Rheumatol 16:338-43. 2004
    ..Histopathologic data and results from clinical trials highlight the predominance of TNF-mediated inflammation in psoriatic joint tissues...
  34. ncbi Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice
    Ping Li
    University of Rochester Medical Center, Rochester, New York 14642, USA
    Arthritis Rheum 50:265-76. 2004
    ..To investigate the mechanisms whereby tumor necrosis factor alpha (TNFalpha) increases osteoclastogenesis in vivo...
  35. ncbi Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography
    Steven T Proulx
    Center for Musculoskeletal Research, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arthritis Rheum 56:4024-37. 2007
    ....
  36. ncbi Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial
    Dafna D Gladman
    University of Toronto, and Toronto Western Hospital, Toronto, Ontario, Canada
    Arthritis Rheum 56:476-88. 2007
    ..To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA)...
  37. ncbi MRI and quantification of draining lymph node function in inflammatory arthritis
    Steven T Proulx
    The Center for Musculoskeletal Research, University of Rochester, Rochester, NY 14642, USA
    Ann N Y Acad Sci 1117:106-23. 2007
    ..63, P = 0.01) between LNcap and synovial volume. TNF-Tg mice with a lower LNcap display an accelerated progression of arthritis. These results indicate a protective function of enhanced lymphatic drainage in inflammatory arthritis...
  38. ncbi Clinical development of anti-RANKL therapy
    Edward M Schwarz
    The Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York 14642, USA
    Arthritis Res Ther 9:S7. 2007
    ....
  39. ncbi Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis
    Christopher T Ritchlin
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Clin Invest 111:821-31. 2003
    ..This leads to osteoclastogenesis at the erosion front and in subchondral bone, resulting in a bidirectional assault on psoriatic bone...
  40. ncbi Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept
    Phillip J Mease
    Seattle Rheumatology Associates, 1101 Madison, Suite 230, Seattle, WA 98104, USA
    J Rheumatol 31:1356-61. 2004
    ..Immune system function can be assessed by evaluating response to vaccination. We assessed the ability of patients with PsA treated with etanercept to produce antibodies in response to pneumococcal antigen challenge...
  41. ncbi Mechanisms of erosion in rheumatoid arthritis
    Christopher T Ritchlin
    J Rheumatol 31:1229-37. 2004
  42. ncbi Outcome measures in psoriatic arthritis
    Dafna D Gladman
    University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto, Canada
    J Rheumatol 32:2262-9. 2005
    ..A set of domains to be included in the assessment of patients with PsA was derived, and a research agenda was developed...
  43. ncbi Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines
    Arthur F Kavanaugh
    University of California at San Diego, San Diego, California, USA
    J Rheumatol 33:1417-21. 2006
    ..We outline the specific methods and procedures used in this evidence-based, systematic review of treatments for PsA, which we hope will provide a basis for future treatment guidelines...
  44. ncbi Metabolic disorders in patients with psoriasis and psoriatic arthritis
    Lotus Mallbris
    Department of Medicine, Dermatology Unit, Karolinska Institutet, 171 76 Stockholm, Sweden
    Curr Rheumatol Rep 8:355-63. 2006
    ....
  45. ncbi Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging
    Steven T Proulx
    University of Rochester, Rochester, New York 14642, USA
    Arthritis Rheum 58:2019-29. 2008
    ..In this study, MRI of murine arthritis was used to elucidate its cellular composition and vascular involvement...
  46. ncbi Consensus on a core set of domains for psoriatic arthritis
    Dafna D Gladman
    J Rheumatol 34:1167-70. 2007
    ..quot;..
  47. ncbi National Psoriasis Foundation clinical consensus on disease severity
    David M Pariser
    Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA
    Arch Dermatol 143:239-42. 2007
    ....